536975-35-6

Upstream product

• 100-39-0 benzyl bromide 
• 115933-50-1 methyl 4-hydroxy-3-(trifluoromethyl)benzoate 
• 1285575-67-8 1-(4-methoxymethoxy-3-trifluoromethylphenyl)ethanone 
• 400629-06-3 2-(trifluoromethyl)phenyl acetate 
• 149105-11-3 1-[4-hydroxy-3-(trifluoromethyl)phenyl]ethan-1-one 
• 115933-49-8 4-benzyloxy-3-trifluoromethylbenzoic acid methyl ester 
• 444-30-4 2-(trifluoromethyl)phenol 
• 67515-55-3 4-fluoro-3-(trifluoromethyl)benzoic acid 
• 100-51-6 benzyl alcohol 

Downstream Products

• 536975-36-7 (4-benzyloxy-3-trifluoromethylphenyl)methanol 
• 1029097-91-3 4-benzyloxy-3-trifluoromethylbenzoyl chloride 
• 1285575-68-9 3-(4-benzyloxy-3-trifluoromethylbenzoyl)-2,3-dihydro-1,3-benzothiazole 
• 1285575-71-4 3-(4-benzyloxy-3-trifluoromethylbenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole 
• 1285573-07-0 3-(4-hydroxy-3-trifluoromethylbenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole 
• 537683-42-4 4-[(4-benzyloxy-3-trifluoromethylbenzyl)[1,2,4]triazol-4-ylamino]benzonitrile 
• 536975-37-8 1-benzyloxy-4-chloromethyl-2-trifluoromethylbenzene 

Relevant academic research and scientific papers

1-[1-(BENZOYL)-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE DERIVATIVES

The present invention relates to 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives having pharmacological activity formula (I) to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of a cognitive disorder.

NOVEL PHENOL DERIVATIVE

Disclosed are a novel compound and a pharmaceutical product, each having a remarkable uricosuric effect. Specifically disclosed are: a novel phenol derivative represented by general formula (1) that is shown in FIG. 1; a pharmaceutically acceptable salt t

AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF

Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.

AGONISTS OF THE SPHINGOSINE- 1- PHOSPHATE RECEPTOR (SLP)

The invention provides compounds of formula I and formula II, their preparation, a their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SlP receptors.

CHEMICAL COMPOUNDS

The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, a

Dual aromatase-steroid sulfatase inhibitors

By introducting the steroid sulfatase inhibitory pharmacophore into aromatase inhibitor 1 (YM511), two series of single agent dual aromatase-sulfatase inhibitors (DASIs) were generated. The best DASIs in'vitro (JEG-3 cells) are 5, (IC50(aromatase) = 0.82 nM; IC 50(sulfatase) = 39 nM), and 14, (IC50(aromatase) = 0.77 nM; IC50(sulfatase) = 590 nM). X-ray crystallography of 5, and docking studies of selected compounds into an aromatase homology model and the steroid sulfatase crystal structure are presented. Both 5 and 14 inhibit aromatase and sulfatase in PMSG pretreated adult female Wistar rats potently 3 h after a single oral 10 mg/kg dose. Almost complete dual inhibition is observed for 5 but the levels were reduced to 85% (aromatase) and 72% (sulfatase) after 24 h. DASI 5 did not inhibit aldosterone synthesis. The development of a potent and selective DASI should allow the therapeutic potential of dual aromatase-sulfatase inhibition in hormone-dependent breast cancer to be assessed.